bioAffinity Technologies, Inc. — Director's Dealing 2022

Dec 5, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-08-29

Reporting Person: KNIGHT PETER S (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.007	14285	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$7.70	2028-05-07	Common Stock (7142)		Direct
Stock Option (right to buy)	$7.70	2029-07-29	Common Stock (7142)		Direct
Stock Option (right to buy)	$7.70	2030-07-27	Common Stock (7142)		Direct
Stock Option (right to buy)	$4.20	2031-12-16	Common Stock (7142)		Direct

Footnotes

F1: The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the Issuer's 2014 Equity Incentive Plan (the "EIP") on May 7, 2018. This option vested in 12 monthly installments beginning on June 7, 2018 and is fully vested and exercisable as of the date of this report.

F3: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on July 29, 2019. This option vested in 12 monthly installments beginning on August 29, 2019 and is fully vested and exercisable as of the date of this report.

F4: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on July 27, 2020. This option vested in 12 monthly installments beginning on August 27, 2020 and is fully vested and exercisable as of the date of this report.

F5: Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Knight under the EIP on December 16, 2021. On January 16, 2022, this option began vesting in 12 monthly installments, the first 11 of which are of 595 shares of Common Stock and the last of which is of the remaining 597 shares of Common Stock, subject to Mr. Knight's continuous service to the Issuer through each vesting date. As of the date of this report, 4,760 shares of Common Stock underlying this option have vested. The remaining unvested shares of Common Stock will vest immediately prior to the closing of the IPO on September 6, 2022.